Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

327.47 +5.36 (+1.66%)

Streaming Delayed Price Updated: 12:27 PM EDT, Apr 13, 2026 Add to My Watchlist

Price and Volume

Volume	285,078
Open	320.66
Bid (Size)	327.23 (120)
Ask (Size)	327.69 (80)
Prev. Close	322.11
Today's Range	319.00 - 328.00
52wk Range	225.84 - 495.55
Shares Outstanding	118,847,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup ↗

April 01, 2026

Via Chartmill

Performance

YTD	-18.2%	-18.2%
1 Month	+4.5%	+4.5%
3 Month	-11.7%	-11.7%
6 Month	-29.6%	-29.6%
1 Year	+36.4%	+36.4%

More News

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

March 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point ↗

March 04, 2026

Via Chartmill

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

March 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast TTR Investor Webinar

March 10, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally ↗

March 05, 2026

Via Stocktwits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Case Study in Affordable Growth ↗

February 27, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗

January 28, 2026

Via Chartmill

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗

January 06, 2026

Via Chartmill

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

Via Investor Brand Network

Why Alnylam Pharmaceuticals Stock Was Soaring on Monday ↗

February 17, 2026

Via The Motley Fool

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

Why Alnylam Pharmaceuticals Stock Slipped Today ↗

February 12, 2026

Via The Motley Fool

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗

January 28, 2026

Via The Motley Fool

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

January 11, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?

Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market

What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?

The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 327.47

When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 04/13/26 12:27 PM ET

What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 38.92B

How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?

Alnylam Pharmaceuticals, Inc. - Common Stock has 39B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.